Navigation Links
BiOptix Continues Support of Antibody Engineering & Therapeutics Research
Date:12/11/2013

BOULDER, Colo. and HUNTINGTON BEACH, Calif., Dec. 11, 2013 /PRNewswire/ -- BiOptix continues support of the global antibody engineering and therapeutics research community through participation in IBC's 24th Annual Antibody Engineering & Therapeutics Conference and annual meeting of The Antibody Society, being held in Huntington Beach, CA from December 8 – 12, 2013.   During the event, BiOptix will be highlighting the BiOptix Innovators Program, a unique and innovative product evaluation platform that allows customers to try BiOptix SPR technology independently in their lab, on their timeframe and with complete customer and technical support during the process. 

While presenting new antibody kinetics data from BiOptix, Ken Wilczek, Vice President, Sales & Marketing for BiOptix noted: "Antibody research and therapeutics continues to be a vital and growing market worldwide—and is a perfect match for the BiOptix 404pi."  "With a unique platform, multiple sensor chemistries and an industry -leading instrumentation demo initiative known as the BiOptix Innovators Program, BiOptix is becoming a principal choice for antibody researchers who require robust and repeatable kinetics."  Additional details about the BiOptix Innovators Program, in which BiOptix seeks to partner with academic, pharmaceutical and biotechnology/drug discovery research labs can be found at:  http://www.bioptix.com/products/innovators-program

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com

 


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BiOptix continues support of Colorado-based research institutions
2. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
3. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
4. AMPAC Fine Chemicals Continues to Invest in Quality Systems
5. Profil Institute Continues to Publish New Findings in Metabolic Research
6. China Cord Blood Corporation Continues Share Repurchase Program
7. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
8. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
9. Green Coffee Extract Continues Dominance Amongst Summers Top Weight Loss Products
10. Z Trim Holdings Sales Growth Continues in July 2012
11. Z Trim Holdings Sales Growth Continues in August 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):